Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Scientists have discovered how to rebuild your cells' protective caps—telomeres—that shorten with age. New research shows telomerase activation can reduce inflammation by 62% and measurably reverse cellular aging markers.
Bioregulator peptides are short-chain amino acid sequences designed to support tissue-specific gene expression that naturally declines with age. Longevity educator Nathalie Niddam explains how personalized peptide strategies, built on solid foundations, may help restore the body's own regulatory signals.
Stem cell scientist Christian Drapeau, founder of Stemregen, reframes everything you thought you knew about stem cells. Moving beyond injections and clinical treatments, this session reveals stem cells as your body's continuous repair system—regenerating your skin monthly, your liver every few years, and even your heart over decades. Drapeau explains how declining stem cell production beginning in our 30s creates cellular deficits that drive aging, and introduces the science of endogenous stem cell mobilization: triggering your bone marrow to release more of your body's own regenerative cells for natural tissue repair and longevity optimization.
Join pioneering stem cell scientist Christian Drapeau, creator of the first stem cell supplement, as he reveals how to unlock your body's natural regenerative potential. Discover the breakthrough science of endogenous stem cell mobilization (ESCM) and learn practical strategies to harness your own stem cells for tissue repair and longevity. Drapeau will share insights from his groundbreaking work at Stemregen on how targeted supplementation can amplify your body's innate ability to heal itself, offering a revolutionary approach to health optimization that works with your biology, not against it.
Discover why measuring intracellular NAD+ levels transforms guesswork into precision optimization, helping you maintain cellular energy and vitality decades longer.
Stem cell availability declines with age, leaving tissues that once healed quickly struggling to repair. Discover how specific botanicals can increase circulating stem cells by up to 80%, restoring your body's natural renewal capacity.
Discover the cutting-edge science behind telomeres—the protective DNA caps that determine cellular aging and lifespan. Sebastian Conti from T.A. Sciences reveals how these molecular timekeepers influence longevity and explores evidence-based strategies to support telomere health. From understanding the latest research on telomere biology to practical interventions that may slow cellular aging, this session provides actionable insights for health optimization. Learn why telomeres are considered the holy grail of aging research and how you can potentially influence your own cellular clock for enhanced healthspan and longevity.
Your body already contains the machinery for regeneration. Researchers are now exploring how perinatal birth tissues, rich in growth factors, extracellular vesicles, and matrix, may hold clues to restoring the repair capacity that declines with age.
Longevity educator and podcaster Nathalie Niddam explores bioregulators—tiny peptide chains that penetrate directly into cells to activate DNA repair and restore gene expression. Drawing from the groundbreaking work of Professor Khavinson's peptide theory of aging, this session demystifies how these two-to-four amino acid complexes differ from conventional peptides, why they don't need receptors to work, and how they address aging at the cellular motherboard. Niddam shares her favorite six "desert island" bioregulators and explains their role in a comprehensive longevity strategy, while navigating the evolving regulatory landscape and distinguishing between synthetic and animal-derived formulations.
What if aging isn't the inevitable decline we've been told it is? Dr. Ian White, regenerative medicine pioneer and founder of Neobiosis, challenges conventional thinking about biological aging by exploring nature's most radical examples—from immortal jellyfish that reverse their age to lobsters that never age at all. Drawing on two decades of stem cell research at Harvard, Cornell, and beyond, he presents compelling evidence that aging can be accelerated, slowed, paused, and even reversed. This provocative session examines the mechanisms behind age reversal, from Yamanaka factors to perinatal tissues, and explores whether regenerative medicine holds the key to treating aging itself as a disease.
Cellular senescence—the accumulation of cells that cease dividing but resist death—has emerged as a primary target in longevity medicine due to evidence that clearing these cells extends healthspan and can address root causes of age-related disease. Senotherapeutics, including senolytics and senomorphics, are transitioning from preclinical studies to clinical trials, though significant challenges in biomarker standardization, cellular heterogeneity, and clinical efficacy remain.
Senotherapeutics—strategies that eliminate or reprogram senescent cells—represent a shift from broad-spectrum senolytic approaches toward precision interventions that target specific cell types and contexts. This progression directly addresses a fundamental mechanism of aging, offering potential to extend healthspan by restoring cellular function rather than relying solely on senescent cell elimination.
Researchers encapsulated healthy mitochondria in red blood cell membranes to deliver them into diseased cells, achieving efficient uptake and functional restoration across multiple cellular models of mitochondrial dysfunction. This addresses a long-standing barrier in mitochondrial replacement therapy and demonstrates potential for treating mitochondrial diseases and age-related energy decline.
Avaí Bio will present clinical data on an encapsulated cell therapy designed to restore circulating α-Klotho, a protein implicated in aging and metabolic regulation. The approach uses Austrianova's Cell-in-a-Box technology to sustain Klotho production, addressing a mechanism that declines with age and correlates with multiple age-related pathologies.
Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.
Springfield Wellness Center has operated for 25 years using intravenous NAD+ therapy as part of a multimodal protocol for addiction recovery and brain restoration. The clinic's longevity and expansion suggest sustained clinical utility, though the evidence base and mechanistic clarity for NAD+ infusions in longevity contexts remain limited.
Klothonova is developing an encapsulated cell therapy designed to restore circulating α-Klotho, a protein that declines with age and influences cardiovascular, renal, and cognitive function. The approach uses genetically modified cells housed in a biocompatible capsule to sustainably produce the protein, addressing a mechanism implicated in multiple age-related conditions.
A systematic review and meta-analysis of allogeneic mesenchymal stromal cell therapies for diabetic foot ulcers found higher rates of complete wound closure and greater reductions in wound size compared to standard care, with no clear signal of serious treatment-related adverse events. The work demonstrates that regenerative cell therapies may support the body's repair capacity when conventional approaches alone prove insufficient in metabolic disease.
Cenegenics has introduced selective plasma exchange technology designed to remove inflammatory proteins, metabolic byproducts, and environmental toxins while preserving beneficial plasma components. The service positions itself as a preventative intervention for individuals managing chronic environmental exposures and systemic inflammation.
Mitrix Bio has reported preliminary Phase 1 safety data from mitochondrial transplantation in two older adults with no observed adverse effects, while simultaneously launching clinics offering the intervention under Right to Try frameworks. This represents a transition from preclinical work to early clinical deployment, though data density remains limited relative to narrative momentum.
BCL XL-PROTAC, a senolytic agent, selectively eliminates senescent cells in COPD airway tissue while promoting proliferation of healthy cells. This approach addresses a core driver of age-related lung disease and suggests a therapeutic pathway for restoring lung cell function in COPD patients.
Avaí Bio and Austrianova have begun GMP-compliant production of a Master Cell Bank for genetically modified cells engineered to overexpress α-Klotho, a protein associated with improved cognitive resilience and organ function in aging. This transition from research to scalable manufacturing represents a critical step toward clinical cell therapy delivery for age-related disease.
GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.
Partial reprogramming of heart muscle cells using three Yamanaka factors (OCT4, SOX2, KLF4) enables cardiomyocytes to complete cell division after myocardial infarction in mice by dismantling their contractile scaffold without triggering uncontrolled proliferation. This approach addresses a fundamental barrier to cardiac regeneration: mature heart cells lose divisibility because their rigid internal structure prevents cytokinesis, even when DNA replication is initiated.
Eli Lilly and PepLib Biotech have formed a collaboration to develop peptide-based therapeutics designed to target specific disease pathways with precision. Peptides represent a distinct therapeutic modality with applications in age-related conditions, metabolic dysfunction, and cardiovascular disease—key drivers of healthspan and lifespan limitations.
MDLifespan and Cenegenics are expanding access to Therapeutic Plasma Exchange (TPE), a procedure that removes environmental toxins, microplastics, and heavy metals from circulation to reduce chronic inflammation. The partnership positions toxin clearance as a foundational longevity strategy, addressing inflammation that undermines cognitive, metabolic, and cardiovascular function.
LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.
Senescent fibroblasts depend on reduced glucose metabolism and maintained chaperone proteins for survival. Inhibiting pyruvate dehydrogenase selectively eliminates senescent cells, including therapy-induced senescent cancer cells, with synergistic enhancement when combined with chaperone inhibition.
Partial cellular reprogramming using three Yamanaka factors (OSK) successfully restored memory function in aged mice and Alzheimer's disease models by rejuvenating memory-encoding neurons while preserving their neuronal identity. This approach demonstrates that targeted reprogramming of engram cells can reverse age-related cognitive decline without causing dedifferentiation or memory loss.
Stem cell therapy demonstrates potential to address frailty in aging by restoring cellular repair capacity and tissue regeneration. This approach targets a fundamental mechanism of aging decline rather than managing symptoms.
Peptides represent a legitimate therapeutic class with demonstrated efficacy, but clinical validation is confined to a narrow subset of compounds. Most peptide applications currently marketed fall outside evidence-supported use, requiring practitioners to distinguish between established interventions and speculative applications.
Cellular reprogramming—the process of resetting aged cells to younger functional states through partial application of reprogramming factors—represents a fundamental shift in how aging is understood: not as irreversible damage accumulation, but as a modifiable biological state. Clinical trials are imminent, and the field has moved from theoretical elegance to therapeutic platform with potential applications across age-associated diseases.
TGFβ signaling emerges as the primary tumor-promoting mechanism within senescent cells induced by platinum chemotherapy in ovarian and lung cancers. Targeting this pathway selectively could preserve the therapeutic benefit of chemotherapy while blocking its pro-tumor effects, addressing a critical vulnerability in current cancer treatment.
FGF21, a growth factor that declines with age, delays intervertebral disc degeneration by upregulating SIRT1 and restoring mitochondrial quality control through the PINK1-Parkin mitophagy pathway. This mechanism addresses a primary driver of age-related lower back pain by counteracting cellular senescence in disc tissue.
